Shares of Zomedica Pharmaceuticals (NYSEMKT:ZOM) fell 13.7% on Thursday after the veterinary health company announced a change to its sales strategy.
Zomedica will build out its internal sales team as it transitions away from its current distributor-based approach. CEO Robert Cohen said the move was precipitated by “changes at our current distributor that we believe have impacted its ability to market our products effectively.” Those words likely startled investors, many of whom decided to sell their shares.
To be fair, Cohen said that while the shift might negatively impact near-term sales of its Truforma diagnostic platform for dogs and cats, it could have some long-term benefits.
“While this effort may slow initial sales of Truforma, we have taken this action now to avoid any disruption to our customers and to provide a stronger foundation on which to build the marketing and sales of both Truforma and any future products developed or acquired by Zomedica,” Cohen said in a press release.
Zomedica recorded its first veterinarian sale of Truforma in mid-March. The diagnostic platform lies at the core of the company’s commercial strategy and is likely to remain its only revenue generator for some time. Investors, in turn, are understandably concerned about a potential slower sales rollout for Truforma.
That said, Zomedica raised roughly $200 million via a share offering in February, so it has the cash it needs to ramp up its sales team. Shareholders will need to be patient with Zomedica’s new approach, but if Truforma is the game changer management says it is, then sales should eventually materialize.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.